Combination of Standard-Dose Pembrolizumab With Reduced-Dose Ipilimumab Tolerable and Effective in Advanced Melanoma

primelines-combination-pembrolizumab-ipilimumab-melanoma

The combination of the programmed death receptor 1 (PD-1) inhibitor nivolumab at a reduced dose (1 mg/kg) with the cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor ipilimumab at standard dose (3 mg/kg) for four doses followed by standard-dose nivolumab alone is a standard of care for patients with advanced, previously untreated melanoma. This is based on[…]

Read More

Inotuzumab Ozogamicin Approved in the US for Adult Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Today the US Food and Drug Administration approved inotuzumab ozogamicin as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). Listen to Dr Elias Jabbour of the MD Anderson Cancer Center provide expert commentary and insights on the clinical trial data leading to the US approval of inotuzumab[…]

Read More

EMA Recommends Approval of Six New Indications for Anticancer Agents in July

EMA-recommendations-primeoncology_2017

On 20 July 2017, the European Medicines Agency (EMA) released positive opinions for six new indications for anticancer therapies. These include new treatments for follicular lymphoma (FL), gastroenteropancreatic neuroendocrine tumors (GEP NETs), Merkel cell carcinoma, urothelial carcinoma, and non-small cell lung cancer (NSCLC). The EMA recommended extending the approval of a CD20-directed antibody obinutuzumab (Gazyvaro®,[…]

Read More

Significant Survival Benefit for Lenalidomide Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma

Multiple myeloma cells

Induction therapy followed by high-dose therapy with autologous stem-cell transplant (ASCT) is a highly effective treatment for transplant–eligible patients with newly diagnosed multiple myeloma (NDMM). However, this treatment is not curative and most patients will experience disease progression. Lenalidomide maintenance after ASCT showed improved progression-free survival (PFS) in several trials, but these trials were not[…]

Read More

Proton Beam Radiotherapy for Stage III Non-Small Cell Lung Cancer

primelines proton therapy NSCLC

For patients with unresectable locally advanced non-small cell lung cancer (NSCLC), concurrent chemoradiotherapy (CRT) is the standard of care. However, CRT may be difficult to tolerate, particularly for patients with comorbidities and suboptimal performance status. The use of proton beam therapy (PBT) is an attractive approach that may lessen the unwanted toxic effects of conventional[…]

Read More

Three New FDA Indications for Anti-Cancer Agents in July

primelines FDA Approvals July 2017 breast cancer melanoma ALL

In July, the US Food and Drug Administration (FDA) granted approval of neratinib for extended adjuvant therapy in early stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, full approval of blinatumomab in relapsed or refractory acute lymphoblastic leukemia (ALL), and expanded the indication for ipilimumab in melanoma to pediatric patients.

Read More

Analysis of Circulating Tumor DNA Superior to Tumor Tissue for Detection of Actionable Mutations in Metastatic Colorectal Cancer

Woman holding model of human intestines in front of body on white background

Mutation testing including RAS and BRAF mutations in metastatic colorectal cancer (mCRC) is mandatory for appropriate treatment selection. Currently mutation analysis is performed using tumor-tissue. However, data on the clinical utility of liquid biopsies (circulating tumor DNA; ctDNA) for mutation analysis are emerging. According to a French multicenter, prospective, blinded study comparing ctDNA analysis to[…]

Read More

Enasidenib, New Targeted Treatment Approach for IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia

August-2017-Post1-GettyImages-678851314-AML blocks-blog

Treatment options for acute myeloid leukemia (AML) are limited, and prognosis, is poor, particularly for older patients, those with secondary AML, and those with relapsed or refractory disease. Recurrent mutations in the isocitrate dehydrogenase 2 gene (IDH2) occur in approximately 12% of patients with AML and may contribute to AML development by blocking myeloid cell[…]

Read More

How Effective Is Nivolumab Beyond Progression in Advanced Melanoma?

Advanced melanoma and nivolumab

A retrospective analysis of two phase III clinical trials published recently in JAMA Oncology has found that treatment of advanced melanoma with nivolumab beyond first disease progression resulted in continued reduction of tumor lesion size in 28% of patients, without significant increase in treatment-related adverse events (AEs). The study pooled results from 526 patients with[…]

Read More

Interesting Articles From the Literature Highlighting Developments in Breast, Colorectal, and Pancreatic Cancer

Recent articles about breast, colorectal, pancreatic cancer

Recommendations for Therapy Escalation in Early Breast Cancer. At the 15th St Gallen International Breast Cancer Conference 2017, an expert panel reviewed new data on treatment paradigms for early breast cancer and issued new recommendations based on their review. The panel recommendations cover locoregional and systemic therapy for early breast cancer, and include a focus[…]

Read More